Introduction
Breast cancer is the most common malignancy and the second cause of cancer-related deaths among women in the United States (Parker et al., 1996) . Although doxorubicin is one of the most effective cytotoxic agents for breast cancer, most patients with advanced-stage breast cancer will recur after doxorubicin-containing chemotherapy (Lebwohl and Canetta, 1999; Levine et al., 1998) . Therefore, it is very important to identify new strategies to overcome the intrinsic and acquired resistance to chemotherapy (Jazirehi et al., 2001; Klement et al., 2002; Seth et al., 1997) .
We hypothesized that the enforced expression of proapoptotic genes, such as tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) gene, would be a useful strategy for the treatment of cancers, including those resistant to apoptosis-inducing chemotherapy. We and others recently demonstrated that transfer of the TRAIL gene or the green fluorescent protein (GFP)/TRAIL fusion gene can induce apoptosis and the apoptotic bystander effect in various human cancer cells (Griffith et al., 2000; Kagawa et al., 2001; Voelkel-Johnson et al., 2002) . However, a drawback of current proapoptotic gene therapy is its toxicity. This could be avoided by targeted gene expression using tumor-specific promoters. In this regard, we also demonstrated that the human telomerase reverse transcriptase (hTERT) promoter, whose gene is active in more than 85% of human cancers but quiescent in most somatic cells (Kim et al., 1994; Shay and Bacchetti, 1997) , could be used to target proapoptotic genes to cancers (Gu et al., 2000) . Moreover, we demonstrated that the GAL4 gene regulatory system can be used to augment transgene expression from a tumor-specific promoter without losing the target specificity . To combine all of these qualities into one treatment, we have created an adenoviral vector that expresses the GFP/TRAIL fusion gene driven by the hTERT promoter via GAL4 gene regulatory components (Ad/gTRAIL).
In this study, we investigated the efficacy of Ad/ gTRAIL in breast cancer cells, including breast cancer cell lines resistant to doxorubicin and in breast cancer xenografts established in nude mice. Treatment with Ad/gTRAIL resulted in the high-level expression of GFP/TRAIL in cancer cells but not in normal human cells. Treatment also elicited apoptosis in malignant cells both sensitive-and resistant-to doxorubicin and suppresses tumor growth, including complete regression in vivo with minimal toxicity to normal cells.
Results

Transgene expression and apoptosis induction by Ad/gTRAIL in vitro in breast cancer cells
To test the levels of transgene expression and the antitumor activity of Ad/gTRAIL, four human breast cancer cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-468, and MCF7) were treated with Ad/ gTRAIL and Ad/CMV-GFP (CMV, cytomegalovirus) at a fixed total multiplicity of infection (MOI), as described in Materials and methods. Cells treated with PBS were used as a mock control. The cells were harvested 48 h after treatment and divided into two parts. One part was used to analyse GFP expression, and the other was used to quantify apoptosis. Cytometry was used for both analyses. Treatment with Ad/CMV-GFP or Ad/gTRAIL resulted in similar levels of GFP-positive cells (70 -90%) in all cell lines ( Figure 1a) . However, only treatment with Ad/ gTRAIL significantly increased the number of apoptotic cells. The induction of apoptosis by Ad/gTRAIL was confirmed by Western blot analysis. Caspase-8, caspase-3, and, poly ADP-ribose polymerase (PARP) cleavage was observed only in cells treated with Ad/ gTRAIL or Ad/GT-TRAIL+Ad/PGK-GV16 (GT, Gal4/TATA; GV16, GAL4/VP16 fusion protein), a binary vector system expressing wild-type TRAIL cDNA from a 3-phosphoglycerate kinase (PGK) promoter (Figure 1b) . The results were validated by cell viability analysis. treatment of the cancer cell lines with Ad/gTRAIL significantly reduced cell viability compared with cells treated with Ad/CMV-GFP or PBS (Figure 1c) . Together, these results suggest that the cancer cell lines tested were highly susceptible to Ad/gTRAIL.
To test whether these cells were similarly sensitive to soluble TRAIL protein, cells were treated with recombinant TRAIL protein at various concentrations up to 800 mg/ml. Cell viability was then determined at 24, 48 and 96 h after treatment. While MDA-MB-231 and MDA-MB-468 were sensitive to TRAIL protein at various concentrations, MDA-MB-453 and MCF7 cells were resistant to TRAIL protein even at a concentration of 800 ng/ml (Figure 2) . Interestingly, however, these two cell lines were as sensitive to Ad/gTRAIL as the other cell lines. Although the mechanisms responsible remain to be characterized, this result suggests that membrane-bound TRAIL may be more effective than soluble TRAIL in certain cells.
Effects of Ad/gTRAIL on doxorubicin resistant cancer cells
To test whether Ad/gTRAIL is also effective in cancers resistant to chemotherapy, we repeatedly treated MDA-MB-231 cells with doxorubicin and selected doxorubicin-resistant cells (231/ADR cells). While parental MDA-MB-231 cells were susceptible to doxorubicin at 2 mM, 231/ADR was resistant to doxorubicin at a concentration of 16 mM (Figure 3a) . Indeed, a subsequent study showed that the IC 50 of a variety of chemotherapeutic agents was increased in 231/ADR cells as compared with parental MDA-MB-231 cells, suggesting that 231/ADR cells are also relatively resistant to many chemotherapy drugs (Table  1) .
We then analysed the ability of Ad/gTRAIL to induce transgene expression and apoptosis in MDA-MB-231 and 231/ADR cells. Flow cytometry showed that levels of transgene expression and apoptosis induced by Ad/gTRAIL were similar in 231/ADR and MDA-MB-231 parental cells (data not shown). And, these results were supported by the 2, 3-bis-(2-methoxy-4-nitro-5-sulphenyl)-(2H)-tetrazolium-5-carboxanilide (XTT) assay (Figure 3b ). The 231/ADR cells were as sensitive to Ad/gTRAIL as the parental cells, suggesting that Ad/gTRAIL is useful for the treatment of cancers resistant to conventional therapy.
Effects of Ad/gTRAIL on normal cells
We were also interested in the ability of Ad/gTRAIL to induce transgene expression and apoptosis in the immortalized non-transformed breast epithelial cell lines MCF10A and MCF10F, normal human mammary epithelial cell (NHMEC), and primary normal human mammary epithelial cells (PNHMEC) isolated from surgical specimens. More than 70% of NHMEC and PNHMEC treated with Ad/CMV-GFP were positive for GFP, whereas only 1% of cells treated with Ad/gTRAIL were positive for GFP. However, only background levels of apoptosis were observed in these two cells after treatment with either Ad/CMV-GFP or Ad/gTRAIL. This finding is consistent with our recent observation that the hTERT promoter is minimally active in normal human cells (Gu et al., 2000) . Interestingly, however, Ad/gTRAIL induced substantial levels of transgene expression and apoptosis in both MCF10A and MCF10F, the two immortalized non-transformed breast cancer cell lines ( Figure 4a ). This result is consistent with our observation in 293 cells, an immortalized human kidney epithelial cell line that has high hTERT promoter activities (Gu et al., 2000) and is sensitive to TRAIL . Cell viability analysis also supported the results from the cytometry assay ( Figure 4b ). In summary, therefore, treatment with Ad/ gTRAIL elicited cell death in MCF10A and MCF10F cells but not in NHMEC and PNHMEC.
Suppression of tumor growth in vivo
To further evaluate the antitumor activity of Ad/ gTRAIL in breast cancer cells, human breast cancer xenografts from MDA-MB-231 were established in 6 -8-week-old nude mice by inoculating tumor cells subcutaneously. The intralesional administration of Ad/gTRAIL or control vector was initiated when tumors reached 0.4 to 0.5 cm in diameter. Animals received a dose of 9610 10 particles/injection/tumor every 5 days for a total of three injections. Tumor 60% of the animals and these animals remained tumorfree for over 5 months. In comparison, tumors treated with Ad/CMV-GFP grew as fast as those treated with PBS, and all animals in these two groups died within 3 months ( Figure 5b ). Histochemical analysis of tumor tissue 2 days after the first injection showed substantial transgene expression in the tumors after treatment with Ad/CMV-GFP or Ad/gTRAIL, However, apoptosis was only observed in the tumors treated with Ad/ gTRAIL ( Figure 5c ). Serum liver enzyme assays of aspartate transaminase (AST) and alanine transaminase (ALT) showed all samples were within normal ranges at 2, 12 and 30 days after the first treatment (data not shown). Similar results were observed in mice bearing tumors derived from the doxorubicin-resistant breast cancer cell line 231/ADR. Mice (10 per group) bearing 231/ ADR tumors were treated with Ad/gTRAIL or Ad/ CMV-GFP as describe above. Ad/gTRAIL significantly suppressed tumor growth as compared with tumor growth in controls (P50.05) (Figure 5d ). In addition, four of the ten animals remained tumor-free at 5 months after treatment with Ad/gTRAIL, whereas all the animals in control groups died of tumor burden during this time period (Figure 5e ).
Discussion
We the cell-killing effects of the TRAIL gene are mainly attributable to membrane-bound TRAIL, as soluble TRAIL was not detected in the media of TRAILexpressing cell cultures . In this study, we evaluated the anti-tumor activity of an adenovector expressing the GFP/TRAIL fusion gene from the hTERT promoter in breast cancer cells. The hTERT promoter was used because it may prevent transgene expression in normal cells (Gu et al., 2000) . Theoretically, this strategy will prevent toxic effects of the TRAIL gene on normal tissues. As hoped, Ad/ gTRAIL treatment elicited transgene expression in breast cancer cells comparable to that induced by Ad/CMV-GFP, but with only minimal levels of transgene expression in normal breast cells. It is unclear whether the activity of the hTERT promoter in our vectors is directly related to levels of endogenous hTERT expression in various cells. Interestingly, we have recently observed transgene expression from the hTERT promoter in Saos-2 cancer cells, which reportedly use an alternative lengthening of telomeres pathway to maintain telomere length rather then using telomeras . Nevertheless, transgene expression in normal cells were substantially lower than that in Saos-2 cells. This suggested that the hTERT promoter can achieve targeted TRAIL gene therapy. Moreover, the intralesional administration of Ad/ gTRAIL resulted in long-term tumor-free in about 50% of animals, suggesting Ad/gTRAIL is a potential anti-tumor agent. Some studies have already revealed that a number of cancer cells lines and fresh tumors are resistant to TRAIL protein (Keane et al., 1999; Nguyen et al., 2001; Voelkel-Johnson et al., 2002) . In our study, we found that the breast cancer cell lines MDA-MB-453 and MCF7 were also relatively resistant to a high dose of TRAIL protein (800 ng/ml), suggesting that recombinant soluble TRAIL protein is not effective enough in some cancers. However, these two cell lines were susceptible to Ad/gTRAIL. We have recently showed that transfer of whole length coding sequence of the TRAIL gene or GFP/TRAIL fusion gene mainly resulted in transgene expression on cell surface . No detectable soluble TRAIL protein was found in media after adenovector-mediated TRAIL gene transfer. It is unclear whether this was because the membrane-bound TRAIL is more effective or the local concentration of TRAIL in cell membranes is higher in the TRAIL gene-transduced cells. Nevertheless, our results suggest that resistance to soluble TRAIL protein does not connote resistance to the TRAIL gene therapy.
Currently, resistance to conventional chemotherapy poses one of the most formidable problems in cancer treatment. Therefore, it will be interesting to determine whether cells resistant to chemotherapy remain sensitive to TRAIL gene therapy. Although our result indicates that these cells remain sensitive to Ad/ gTRAIL, it was somewhat expected because the cellkilling mechanisms of the TRAIL protein and doxorubicin are likely to be completely different (De Jong et al., 2001; Nagane et al., 2001; Stewart and Ratain, 2001) , although overexpression of some antiapoptotic proteins, such as Bcl2 or BclX L may result in resistance to both molecules. Therefore, tumors resistant to chemotherapy may not be resistant to the TRAIL gene therapy (Voelkel-Johnson et al., 2002) . Our results also suggest that proapoptotic gene therapy is useful for the treatment of tumors resistant to conventional therapy. Unfortunately, in a recent study of proapoptotic gene therapy in colon cancer, we observed that the repeated application of adenovectors expressing proapoptotic genes also resulted in the selection and expansion of cells resistant to such a treatment . Thus, multi-modality therapy or combining therapy of chemotherapeutic agents and proapoptotic genes may be one solution in combating resistance.
Materials and methods
Cell lines and reagents
Human breast cancer cell lines MCF7, MDA-MB-231, MDA-MB-453, and MDA-MB-468 were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum, and antibiotics, and glutamine. Immortalized non-transformed breast epithelial cell lines MCF10A and MCF10F and normal human mammary epithelial cells (NHMEC) purchased from Clonetics (San Diego, CA, USA), were cultured in medium recommended by the manufacturer. Primary normal human mammary epithelial cells (PNHMEC) isolated from normal breast tissue (Stampfer and Yaswen, 1994) were provided by Dr Yinhua Yu (The University of Texas M. D. Anderson Cancer Center, USA). Doxorubicin-resistant MDA-MB-231 cells were obtained through the stepwise exposure of the parental cells to doxorubicin. In brief, the parental MDA-MB-231 cells were treated with doxorubicin (Ben Venue Labs, Inc., Bedford, OH, USA) at a concentration of 2 mM (1.16 mg/ ml, which is the IC 80 of MDA-MB-231 cells). Most cells were killed after day 4 of treatment. The residual surviving cells were then allowed to grow in fresh medium. When these residual cells reached 70 -80% confluence in the plate, they were treated again with the same concentration of doxorubicin. After this cycle was repeated several times, the concentration of doxorubicin was increased multiple times followed by the regrowth of cells. Finally, MDA-MB-231 resistant to doxorubicin at a concentration of 16 mM were selected for use in the subsequent experiments. Other agents used in these experiments included gemcitabine (Eli Lilly and Co., Indianapolis, IN, USA), vinorelbine (Pierre Fabre, Idron 64320, France), paclitaxel (Bristol-Myers Squibb Co., Princeton, NJ, USA), irinotecan (Pharmacia & Upjohn Co., Kalamazoo, MI, USA), floxuridine (Ben Venue Labs, Inc., Bedford, OH, USA), and TRAIL protein (R&D Systems, Minneapolis, MN, USA).
Adenovectors
Adenovectors Ad/CMV-LacZ, Ad/PGK-GV16, Ad/CMV-GFP, Ad/GT-TRAIL and Ad/gTRAIL have been described previously (Gu et al., 2000; Kagawa et al., 2001; Zhang et al., 2002) . The expansion, purification, titration, and quality analysis of all vectors used were performed at the vector core facility of our institution as described previously (Gu et al., Ad/gTRAIL in breast cancer cells T Lin et al 2000; Kagawa et al., 2001) . All viral preparations were shown to be free of the E1+adenovirus by PCR assay and of endotoxin by a Limulus amebocyte lysate endotoxin detection kit (BioWhittaker, Walkersville, MD, USA). The titer used in this study was determined by the absorbency of the dissociated virus at A260 nm (one A260 nm unit=10 12 viral particles/ml), while titers determined by the plaque assay were used to obtain additive information. Particles: Infectious unit (IU) ratios were usually between 30 : 1 and 100 : 1. Thus, the multiplicity of infection (MOI) of 1000 vp is equivalent to an MOI of 10-30 IU. The optimal MOI for each cell line was determined by infecting each cell line with Ad/CMV-LacZ and assessing the expression of b-galactosidase via 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-gal) staining. The MOIs used in this experiment were those that resulted in 50 -80% of cells being stained blue. The MOIs for each of the cell lines were as follows: 2000 particles for MDA-MB-468, 4000 particles for MDA-MB-231, 231/ADR and MDA-MB-453, 8000 particles for MCT respectively. The MOI of MCF-10A, MCF10F, NPMEC and NHME were 4000 particles. Unless otherwise specified, Ad/CMV-GFP was used as a vector control and PBS as a mock control.
Cell viability assay
Cell viability was determined by an XTT assay (Cell Proliferation Kit II, Roche Molecular Biochemicals, Indianapolis, IN, USA) according to the manufacturer's protocol as we have described previously (Gu et al., 2000; . Each experiment was performed in quadruplicate and repeated at least twice.
Flow cytometry assay
The flow cytometry assay was performed as described previously (Gu et al., 2000; Kagawa et al., 2001) . In brief, both adherent and floating cells were harvested 48 h after treatment. One part was used for the analysis of GFP expression, which involved determining the percentage of GFP-positive cells using a FACS system (Becton-Dickinson, Mansfield, MA, USA). The second part of the sample, which was fixed by 70% ethanol overnight and stained with propidium iodide (1 ml PI, 10 ml RNase, 9 ml PBS, PI: 50 mg/ml) before analysis, was used to quantify the apoptotic cells. This was done using flow cytometry, which measured the sub G0/G1 cellular DNA content using Cell Quest software (Becton-Dickinson, San Jose, CA, USA).
Biochemical analysis
For the b-galactosidase analysis, cells were harvested 48 h after treatment and lysed in b-galactosidase assay buffer. Cell pellets were then removed by microcentrifugation. The protein concentration of the supernate were determined according to the manufacturer's instructions using a kit from Pierce chemical company (Rockford, IL, USA). b-Galactosidase activities were determined using a luminometer and a Galactolight chemiluminescent assay kit from Tropix, Inc. (Bedford, MA, USA). Western blot analysis was performed as described previously (Gu et al., 2000; Kagawa et al., 2001) . Antibodies used in this study were anti-caspase-8 (R&D systems, Minneapolis, MN, USA), anti-caspase-3 (BD PharMingen, San Diego, CA, USA), anti-PARP (BD PharMingen), anti-GFP (Clontech Inc., Palo Alto, CA, USA), and anti-hTRAIL (Alexis, San Diego, CA, USA).
Animal experiments
Animal experiments were carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals (NIH publication number 85-23) and the institutional guidelines of The University of Texas M. D. Anderson Cancer Center. Human breast cancer xenografts were established in 6 -8-week-old nude mice (Charles River Laboratories Inc., Washington, MA) by subcutaneous inoculation of 5610 6 MDA-MB-231 or 231/ADR cells into the dorsal flank of each mouse. The intratumoral injection of adenovectors or PBS was performed when the tumors reached 0.5 cm in diameter. Intratumoral injections were given once every 5 days for a total of three times at 9610 10 particles/injection/tumor. Mice were then followed-up three times a week to measure the sizes of the tumor using calipers. The volume of the tumor was calculated as follows: a6b 2 /2, with a the largest diameter and b the smallest diameter. The mouse was sacrificed according to institutional guidelines when the tumor reached 1.5 cm in diameter. Blood samples were collected from the tail vein over time after the treatment to monitor liver function. The levels of serum ASR and ALT were measured as described previously (Gu et al., 2000; Kagawa et al., 2001) .
TUNEL staining
Apoptosis in tumors, which were resected 48 h after intratumoral injection, was assessed by in situ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining. Briefly, the paraffin-embedded sections were deparaffinized and dehydrated. The slides were incubated in 3% H 2 O 2 in methanol for 10 min at room temperature and then with 0.02% protease/PBS for 30 min at 378C. After incubation with reaction buffer containing terminal deoxyribonucleotidyl transferase according to the manufacturer's protocol (Roche Molecular Biochemicals), the slides were stained with ABC reagent. After this, the slides were incubated with DAB/H 2 O 2 solutions and restained with 4% methyl green after complete washing.
Statistical analysis
Differences among the treatment groups were assessed by ANOVA using statistical software (Statistica, Tulsa, OK, USA). Differences in tumor growth in vivo among the treatment groups were assessed by ANOVA with a repeated measurement module. A value of P40.05 was considered significant. Survival was assessed using the Kaplan -Meier method. The drug concentration that inhibited cells growth by 50% (IC 50 ) was calculated by Curve Expert 1.3 software (Starksville, MS, USA).
